Concepts (210)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Immunotherapy, Adoptive | 19 | 2025 | 884 | 3.230 |
Why?
|
| T-Lymphocytes | 21 | 2024 | 1814 | 2.810 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 14 | 2025 | 1188 | 2.660 |
Why?
|
| Leukemia, Myeloid, Acute | 7 | 2024 | 569 | 1.830 |
Why?
|
| Antigens, CD19 | 5 | 2025 | 181 | 1.410 |
Why?
|
| Myelodysplastic Syndromes | 2 | 2021 | 129 | 1.310 |
Why?
|
| Lymphocyte Transfusion | 2 | 2021 | 58 | 1.220 |
Why?
|
| Receptors, Antigen, T-Cell | 7 | 2023 | 501 | 1.060 |
Why?
|
| Lymphoma | 3 | 2024 | 335 | 0.990 |
Why?
|
| Lymphoma, Non-Hodgkin | 2 | 2018 | 168 | 0.990 |
Why?
|
| Multiple Myeloma | 3 | 2022 | 201 | 0.890 |
Why?
|
| Hematologic Neoplasms | 2 | 2024 | 294 | 0.860 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 2 | 2022 | 149 | 0.820 |
Why?
|
| Hodgkin Disease | 4 | 2022 | 298 | 0.820 |
Why?
|
| Graft vs Host Disease | 3 | 2024 | 622 | 0.820 |
Why?
|
| Salvage Therapy | 2 | 2021 | 202 | 0.790 |
Why?
|
| Leukemia | 2 | 2024 | 380 | 0.790 |
Why?
|
| T-Lymphocytes, Cytotoxic | 3 | 2024 | 522 | 0.780 |
Why?
|
| Cell- and Tissue-Based Therapy | 5 | 2023 | 170 | 0.720 |
Why?
|
| Graft vs Leukemia Effect | 1 | 2021 | 36 | 0.710 |
Why?
|
| Bone Marrow | 2 | 2024 | 334 | 0.680 |
Why?
|
| Cyclin A1 | 1 | 2020 | 4 | 0.670 |
Why?
|
| Leukemia, Myeloid | 1 | 2020 | 82 | 0.650 |
Why?
|
| Bone Marrow Cells | 1 | 2021 | 273 | 0.640 |
Why?
|
| Adoptive Transfer | 2 | 2020 | 241 | 0.630 |
Why?
|
| Antigens, Neoplasm | 4 | 2024 | 407 | 0.620 |
Why?
|
| Recombinant Fusion Proteins | 2 | 2018 | 801 | 0.570 |
Why?
|
| Precursor T-Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2019 | 92 | 0.570 |
Why?
|
| Transplantation, Homologous | 5 | 2024 | 693 | 0.550 |
Why?
|
| Fusion Proteins, bcr-abl | 1 | 2017 | 42 | 0.530 |
Why?
|
| Neoplasms | 4 | 2024 | 3025 | 0.490 |
Why?
|
| Humans | 51 | 2025 | 133854 | 0.490 |
Why?
|
| Immunotherapy | 5 | 2024 | 747 | 0.470 |
Why?
|
| Virus Diseases | 3 | 2023 | 289 | 0.460 |
Why?
|
| Niacinamide | 1 | 2013 | 29 | 0.410 |
Why?
|
| Phenylurea Compounds | 1 | 2013 | 56 | 0.400 |
Why?
|
| Vasculitis, Leukocytoclastic, Cutaneous | 1 | 2011 | 5 | 0.360 |
Why?
|
| Paraneoplastic Syndromes | 1 | 2011 | 19 | 0.360 |
Why?
|
| Neoplasm Recurrence, Local | 5 | 2024 | 1314 | 0.340 |
Why?
|
| Combined Modality Therapy | 5 | 2021 | 1315 | 0.330 |
Why?
|
| Recurrence | 3 | 2024 | 1467 | 0.320 |
Why?
|
| Leukemia, Lymphocytic, Chronic, B-Cell | 1 | 2011 | 178 | 0.320 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 4 | 2024 | 1354 | 0.290 |
Why?
|
| Tissue Donors | 2 | 2021 | 525 | 0.280 |
Why?
|
| Antineoplastic Agents | 2 | 2018 | 1850 | 0.270 |
Why?
|
| Remission Induction | 3 | 2020 | 308 | 0.270 |
Why?
|
| Clinical Trials as Topic | 2 | 2024 | 1153 | 0.260 |
Why?
|
| Lymphocyte Activation | 2 | 2019 | 724 | 0.260 |
Why?
|
| Herpesvirus 4, Human | 3 | 2024 | 676 | 0.250 |
Why?
|
| Adult | 17 | 2025 | 31925 | 0.240 |
Why?
|
| Transplantation, Autologous | 2 | 2022 | 286 | 0.230 |
Why?
|
| Glypicans | 1 | 2024 | 41 | 0.230 |
Why?
|
| Carboplatin | 1 | 2024 | 87 | 0.220 |
Why?
|
| Alemtuzumab | 1 | 2024 | 88 | 0.220 |
Why?
|
| Deoxycytidine | 1 | 2024 | 84 | 0.220 |
Why?
|
| Neurotoxicity Syndromes | 1 | 2025 | 63 | 0.220 |
Why?
|
| Male | 20 | 2025 | 65815 | 0.220 |
Why?
|
| Interleukin-15 | 1 | 2024 | 96 | 0.220 |
Why?
|
| Carcinoma, Hepatocellular | 1 | 2013 | 999 | 0.220 |
Why?
|
| T-Cell Antigen Receptor Specificity | 2 | 2021 | 57 | 0.220 |
Why?
|
| Allografts | 2 | 2022 | 197 | 0.210 |
Why?
|
| Middle Aged | 16 | 2025 | 29371 | 0.210 |
Why?
|
| Lymphoma, T-Cell | 1 | 2024 | 65 | 0.210 |
Why?
|
| Treatment Outcome | 6 | 2025 | 13011 | 0.210 |
Why?
|
| Quinazolines | 1 | 2024 | 184 | 0.210 |
Why?
|
| Lymphoma, B-Cell | 1 | 2025 | 150 | 0.210 |
Why?
|
| Isocitrate Dehydrogenase | 1 | 2024 | 83 | 0.210 |
Why?
|
| Leukocytes, Mononuclear | 3 | 2022 | 358 | 0.200 |
Why?
|
| Cytomegalovirus Infections | 1 | 2024 | 228 | 0.190 |
Why?
|
| Liver Neoplasms | 1 | 2013 | 1410 | 0.190 |
Why?
|
| Aged | 11 | 2025 | 21717 | 0.190 |
Why?
|
| Vulnerable Populations | 1 | 2023 | 148 | 0.190 |
Why?
|
| Hematopoiesis | 1 | 2023 | 229 | 0.190 |
Why?
|
| Antiviral Agents | 2 | 2024 | 822 | 0.180 |
Why?
|
| Lymphocytes | 1 | 2023 | 440 | 0.180 |
Why?
|
| Young Adult | 8 | 2025 | 9885 | 0.180 |
Why?
|
| Anemia, Sickle Cell | 1 | 2025 | 341 | 0.180 |
Why?
|
| Genetic Engineering | 2 | 2019 | 164 | 0.170 |
Why?
|
| Ki-1 Antigen | 1 | 2020 | 29 | 0.170 |
Why?
|
| Demography | 1 | 2021 | 247 | 0.170 |
Why?
|
| Immunologic Factors | 1 | 2021 | 184 | 0.160 |
Why?
|
| Immunity, Cellular | 2 | 2017 | 217 | 0.160 |
Why?
|
| Prognosis | 4 | 2021 | 5070 | 0.160 |
Why?
|
| Chromatin | 1 | 2022 | 609 | 0.160 |
Why?
|
| Th1 Cells | 1 | 2020 | 159 | 0.150 |
Why?
|
| Lymphocyte Depletion | 3 | 2024 | 125 | 0.150 |
Why?
|
| Lentivirus | 1 | 2018 | 86 | 0.140 |
Why?
|
| DNA Virus Infections | 1 | 2017 | 22 | 0.140 |
Why?
|
| Parainfluenza Virus 3, Human | 1 | 2017 | 12 | 0.140 |
Why?
|
| Respirovirus Infections | 1 | 2017 | 20 | 0.140 |
Why?
|
| DNA Viruses | 1 | 2017 | 33 | 0.140 |
Why?
|
| Paramyxoviridae Infections | 1 | 2017 | 49 | 0.140 |
Why?
|
| Metapneumovirus | 1 | 2017 | 52 | 0.140 |
Why?
|
| Lectins, C-Type | 1 | 2017 | 76 | 0.140 |
Why?
|
| Blood Platelets | 1 | 2019 | 341 | 0.130 |
Why?
|
| Plasmids | 1 | 2018 | 527 | 0.130 |
Why?
|
| Receptors, Antigen | 1 | 2016 | 34 | 0.130 |
Why?
|
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 1 | 2017 | 101 | 0.130 |
Why?
|
| Adolescent | 7 | 2025 | 20517 | 0.130 |
Why?
|
| Female | 15 | 2025 | 71586 | 0.120 |
Why?
|
| Antigens, Viral | 1 | 2017 | 440 | 0.120 |
Why?
|
| Cell Line, Tumor | 2 | 2020 | 3751 | 0.120 |
Why?
|
| Survival Analysis | 1 | 2018 | 1596 | 0.110 |
Why?
|
| Genetic Vectors | 1 | 2018 | 970 | 0.110 |
Why?
|
| Small Cell Lung Carcinoma | 1 | 2013 | 38 | 0.100 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2018 | 820 | 0.100 |
Why?
|
| Child | 6 | 2024 | 25712 | 0.100 |
Why?
|
| Hyponatremia | 1 | 2013 | 76 | 0.100 |
Why?
|
| Carcinoma, Small Cell | 1 | 2011 | 50 | 0.090 |
Why?
|
| Epstein-Barr Virus Infections | 2 | 2024 | 295 | 0.090 |
Why?
|
| Cytomegalovirus | 2 | 2024 | 271 | 0.090 |
Why?
|
| Anti-HIV Agents | 1 | 2013 | 344 | 0.080 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2013 | 506 | 0.080 |
Why?
|
| HIV-1 | 1 | 2013 | 488 | 0.080 |
Why?
|
| CD8-Positive T-Lymphocytes | 2 | 2024 | 444 | 0.080 |
Why?
|
| Retrospective Studies | 6 | 2024 | 17457 | 0.070 |
Why?
|
| Cytokines | 3 | 2019 | 1396 | 0.070 |
Why?
|
| Myeloid Cells | 2 | 2018 | 120 | 0.070 |
Why?
|
| Registries | 1 | 2013 | 1561 | 0.060 |
Why?
|
| Bone Neoplasms | 1 | 2011 | 447 | 0.060 |
Why?
|
| Xenograft Model Antitumor Assays | 2 | 2019 | 1006 | 0.060 |
Why?
|
| Breast Neoplasms | 1 | 2018 | 2764 | 0.060 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2013 | 2196 | 0.060 |
Why?
|
| Nasopharyngeal Neoplasms | 1 | 2024 | 62 | 0.060 |
Why?
|
| Acetates | 1 | 2024 | 80 | 0.060 |
Why?
|
| Standard of Care | 1 | 2025 | 136 | 0.050 |
Why?
|
| Cohort Studies | 2 | 2024 | 5173 | 0.050 |
Why?
|
| Adenocarcinoma | 1 | 2011 | 1070 | 0.050 |
Why?
|
| Biological Products | 1 | 2025 | 137 | 0.050 |
Why?
|
| Medically Underserved Area | 1 | 2023 | 94 | 0.050 |
Why?
|
| Fas Ligand Protein | 1 | 2022 | 38 | 0.050 |
Why?
|
| Proteasome Inhibitors | 1 | 2022 | 65 | 0.050 |
Why?
|
| Genes, myc | 1 | 2022 | 107 | 0.050 |
Why?
|
| Neutropenia | 1 | 2024 | 201 | 0.050 |
Why?
|
| Interleukin-6 | 1 | 2024 | 453 | 0.050 |
Why?
|
| Carmustine | 1 | 2022 | 25 | 0.050 |
Why?
|
| Thrombocytopenia | 1 | 2024 | 235 | 0.050 |
Why?
|
| Melphalan | 1 | 2022 | 45 | 0.050 |
Why?
|
| Autografts | 1 | 2022 | 29 | 0.050 |
Why?
|
| Cytarabine | 1 | 2022 | 100 | 0.050 |
Why?
|
| HLA Antigens | 1 | 2023 | 253 | 0.050 |
Why?
|
| Prostatic Neoplasms | 1 | 2011 | 1623 | 0.050 |
Why?
|
| Minority Groups | 1 | 2023 | 255 | 0.050 |
Why?
|
| Proteasome Endopeptidase Complex | 1 | 2022 | 271 | 0.050 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2013 | 3843 | 0.040 |
Why?
|
| HIV Infections | 1 | 2013 | 2066 | 0.040 |
Why?
|
| Rituximab | 1 | 2022 | 164 | 0.040 |
Why?
|
| Bendamustine Hydrochloride | 1 | 2020 | 15 | 0.040 |
Why?
|
| Vidarabine | 1 | 2020 | 78 | 0.040 |
Why?
|
| Lung Neoplasms | 1 | 2011 | 1789 | 0.040 |
Why?
|
| Transplantation Conditioning | 1 | 2022 | 299 | 0.040 |
Why?
|
| Receptors, CCR7 | 1 | 2019 | 22 | 0.040 |
Why?
|
| Killer Cells, Natural | 1 | 2022 | 357 | 0.040 |
Why?
|
| CD28 Antigens | 1 | 2019 | 81 | 0.040 |
Why?
|
| Chronic Disease | 1 | 2024 | 1253 | 0.040 |
Why?
|
| Coculture Techniques | 1 | 2019 | 246 | 0.040 |
Why?
|
| Antigens, CD7 | 1 | 2018 | 11 | 0.040 |
Why?
|
| Immunophenotyping | 1 | 2019 | 342 | 0.040 |
Why?
|
| Epitopes | 1 | 2020 | 446 | 0.040 |
Why?
|
| Stem Cell Transplantation | 1 | 2020 | 250 | 0.040 |
Why?
|
| Cell Culture Techniques | 1 | 2019 | 292 | 0.040 |
Why?
|
| Immunologic Memory | 1 | 2019 | 199 | 0.040 |
Why?
|
| Cyclophosphamide | 1 | 2020 | 418 | 0.040 |
Why?
|
| Tumor Microenvironment | 1 | 2022 | 689 | 0.040 |
Why?
|
| Granzymes | 1 | 2017 | 48 | 0.040 |
Why?
|
| Disease Models, Animal | 2 | 2019 | 4772 | 0.030 |
Why?
|
| Immunodominant Epitopes | 1 | 2017 | 52 | 0.030 |
Why?
|
| Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2017 | 69 | 0.030 |
Why?
|
| Gene Editing | 1 | 2019 | 212 | 0.030 |
Why?
|
| Adenoviruses, Human | 1 | 2017 | 99 | 0.030 |
Why?
|
| Cell Survival | 1 | 2019 | 891 | 0.030 |
Why?
|
| Herpesvirus 6, Human | 1 | 2017 | 55 | 0.030 |
Why?
|
| BK Virus | 1 | 2017 | 61 | 0.030 |
Why?
|
| Malocclusion | 1 | 1976 | 11 | 0.030 |
Why?
|
| Mice | 3 | 2019 | 18884 | 0.030 |
Why?
|
| Cytotoxicity, Immunologic | 1 | 2017 | 277 | 0.030 |
Why?
|
| Mandible | 1 | 1976 | 82 | 0.030 |
Why?
|
| Inflammation Mediators | 1 | 2017 | 262 | 0.030 |
Why?
|
| Immunocompromised Host | 1 | 2017 | 304 | 0.030 |
Why?
|
| Interferon-gamma | 1 | 2017 | 538 | 0.030 |
Why?
|
| Child, Preschool | 2 | 2024 | 14776 | 0.030 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2017 | 707 | 0.030 |
Why?
|
| Feasibility Studies | 1 | 2017 | 817 | 0.030 |
Why?
|
| Quality of Life | 1 | 2024 | 2132 | 0.030 |
Why?
|
| Aged, 80 and over | 2 | 2017 | 7200 | 0.030 |
Why?
|
| CD4 Lymphocyte Count | 1 | 2013 | 239 | 0.030 |
Why?
|
| Animals | 3 | 2019 | 36364 | 0.020 |
Why?
|
| Follow-Up Studies | 1 | 2022 | 5505 | 0.020 |
Why?
|
| Gene Expression | 1 | 2017 | 1614 | 0.020 |
Why?
|
| Cross-Sectional Studies | 1 | 2021 | 3738 | 0.020 |
Why?
|
| United States | 2 | 2021 | 11682 | 0.020 |
Why?
|
| Cell Proliferation | 1 | 2019 | 2539 | 0.020 |
Why?
|
| Antiretroviral Therapy, Highly Active | 1 | 2013 | 269 | 0.020 |
Why?
|
| Cell Differentiation | 1 | 2019 | 2026 | 0.020 |
Why?
|
| Viral Load | 1 | 2013 | 412 | 0.020 |
Why?
|
| Etoposide | 1 | 2011 | 120 | 0.020 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2013 | 1139 | 0.020 |
Why?
|
| Androgen Antagonists | 1 | 2011 | 131 | 0.020 |
Why?
|
| Mutation | 1 | 2024 | 6289 | 0.020 |
Why?
|
| Biomarkers | 1 | 2019 | 3422 | 0.020 |
Why?
|
| Proportional Hazards Models | 1 | 2013 | 1482 | 0.020 |
Why?
|
| Cisplatin | 1 | 2011 | 287 | 0.020 |
Why?
|
| Comorbidity | 1 | 2013 | 1614 | 0.020 |
Why?
|
| Incidence | 1 | 2013 | 3393 | 0.020 |
Why?
|
| Veterans | 1 | 2013 | 1766 | 0.010 |
Why?
|
| Infant | 1 | 2017 | 13135 | 0.010 |
Why?
|
| Risk Factors | 1 | 2013 | 11078 | 0.010 |
Why?
|
| Cephalometry | 1 | 1976 | 35 | 0.010 |
Why?
|
| Rotation | 1 | 1976 | 52 | 0.010 |
Why?
|
| Patient Care Planning | 1 | 1976 | 133 | 0.010 |
Why?
|